PPARA and steatosis: Lanifibranor (IVA337), a pan-PPAR ligand that stimulates PPAR-α, -δ, and -γ, was reported to decrease the SAF (steatosis, activity, and fibrosis) score in patients with active NASH108,109 and is now in a phase 3 study (NCT04849728).